What question did this study set out to answer?

To review the development of platelet glycoprotein IIb/IIIa receptor antagonists and examine their clinical efficacy across cardiovascular interventions.

January 1, 1998Japanese Circulation Journal-english EditionOpen Access

The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine

View Full Paper

Ask AI

Bookmark

Why the study?

Does platelet glycoprotein IIb/IIIa receptor blockade reduce ischemic complications in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?

Population

Patients with acute coronary syndromes and those undergoing percutaneous coronary revascularization procedures

Design

Review

Authors

KMKoon‐Hou MakGleneagles Hospital ATArthur TanSingapore General Hospital CCCharles ChanHong Kong Polytechnic University

Discussion

Member takes

Implication

Supports adjunctive GP IIb/IIIa blockade in PCI; leaves open definitive ACS role pending randomized trials.

Key Points

To review the development of platelet glycoprotein IIb/IIIa receptor antagonists and examine their clinical efficacy across cardiovascular interventions.
Synthesized findings from preclinical investigations and early clinical trials testing monoclonal antibodies and peptide-based antagonists.
Evaluated procedural and therapeutic outcomes in patients undergoing percutaneous coronary revascularization and treatment for acute coronary syndromes.
Glycoprotein IIb/IIIa receptor blockade demonstrated substantial clinical benefit by curbing platelet-mediated ischemic complications during percutaneous revascularization.
Encouraging preliminary outcomes supported broadening the application of these receptor antagonists to standard medical management of acute coronary syndromes.

Structured PICO

Does platelet glycoprotein IIb/IIIa receptor blockade reduce ischemic complications in patients with acute coronary syndromes or undergoing percutaneous coronary revascularization?

Population

Patients with acute coronary syndromes and those undergoing percutaneous coronary revascularization procedures

Intervention

Platelet glycoprotein IIb/IIIa receptor blockade (including monoclonal antibodies, peptide, and peptide-like substances)

Platelet glycoprotein IIb/IIIa receptor blockade represents a promising pharmacological strategy for reducing ischemic complications in acute coronary syndromes and percutaneous coronary interventions.

Cite This Study

Mak et al. (1998) studied this question.

synapsesocial.com/papers/6a86739c894d3eb3a35afc19 https://doi.org/10.1253/jcj.62.233

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider